Aldosterone and the kidney

Hormone and Metabolic Research

Volumn 44, Issue 3, 2012, Pages 194-201

  Fourkiotis, V G ^a   Hanslik, G ^a   Hanusch, F ^a   Lepenies, J ^b   Quinkler, M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b KfH Dialysis Center   (Germany)

Author keywords

albuminuria; aldosterone; chronic kidney disease; primary hyperaldosteronism; renal inflammation

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALBUMIN; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 2 MICROGLOBULIN; CILAZAPRIL; COLLAGEN TYPE 3; CORTISONE; CREATININE; DEOXYCORTICOSTERONE; DESMIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPLERENONE; FAD 286; FASUDIL; HYDROCORTISONE; INTERLEUKIN 1; INTERLEUKIN 6; LCI 699; LOSARTAN; MESSENGER RNA; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; OSTEOPONTIN; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ADRENALECTOMY; ALBUMINURIA; ALDOSTERONE BLOOD LEVEL; ANEMIA; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTERY RESISTANCE; CARDIOVASCULAR RISK; CAROTID ARTERY; CELL AGING; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DISEASE COURSE; DNA DAMAGE; ESSENTIAL HYPERTENSION; GLOMERULUS FILTRATION RATE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPERTENSION RETINOPATHY; HYPOKALEMIA; INFLAMMATION; KIDNEY; METABOLIC BONE DISEASE; MICROALBUMINURIA; NONHUMAN; OXIDATIVE STRESS; PODOCYTE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; PULSE WAVE; RENAL PROTECTION; REVIEW; SIDE EFFECT; SMOOTH MUSCLE FIBER; SODIUM RESTRICTION; SODIUM RETENTION; SYSTOLIC BLOOD PRESSURE; UREMIA; URINARY ALBUMIN EXCRETION; URINARY EXCRETION; VASCULAR SMOOTH MUSCLE;

ALDOSTERONE; ANIMALS; HUMANS; HYPERALDOSTERONISM; KIDNEY; KIDNEY DISEASES; RECEPTORS, MINERALOCORTICOID;

EID: 84858008314     PISSN: 00185043     EISSN: 14394286     Source Type: Journal    
DOI: 10.1055/s-0031-1295461     Document Type: Review

References (105)

1. Fuller P J, Young M J. Mechanisms ofMineralocorticoid Action. Hypertension 2005; 46: 1227-1235
2. Danforth D N Jr, Orlando M M, Bartter FC, Javadpour N. Renal changes in primary aldosteronism. J Urol 1977; 117: 140-144 (Pubitemid 8047826)
3. Hené R J, Boer P, Koomans H A, Mees E J. Plasma aldosterone concentrations in chronic renal disease. Kidney Int 1982; 21: 98-101 (Pubitemid 12135754)
4. Walker W G. Hypertension-related renal injury: a major contributor to end-stage renal disease. Am J Kidney Dis 1993; 22: 164-173 (Pubitemid 23203515)
5. Halimi J M, Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension. J Hypertens 1995; 13: 1801-1802 (Pubitemid 26015820)
6. Fox C S, Larson M G, Hwang S-J, Leip E P, Rifai N, Levy D, Benjamin E J, Murabito J M, Meigs J B, Vasan R S. Cross-sectional relations ofserum aldosterone and urine sodium excretion to urinary albumin excretion in a community-based sample. Kidney Int 2006; 69: 2064-2069 (Pubitemid 43924272)
7. Wakisaka M, Spiro M J, Spiro R G. Synthesis oftype VI collagen by cultured glomerular cells and comparison ofits regulation by glucose and other factors with that oftype IV collagen. Diabetes 1994; 43: 95-103
8. Briet M, Schiffrin E L. Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 2010; 6: 261-273
9. Levey A S, Coresh J, Balk E, Kausz A T, Levin A, Steffes M W, Hogg R J, Perrone R D, Lau J, Eknoyan G. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137-147
10. Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, Narita M, Koyama A. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int 2006; 71: 159-166
11. Levey A S, Coresh J. Chronic kidney disease. Lancet 2011 [Epub ahead ofprint]; available from http://www.ncbi.nlm.nih.gov/ pubmed/21840587
12. Peterson J C, Adler S, Burkart J M, Greene T, Hebert L A, Hunsicker L G, King A J, Klahr S, Massry S G, Seifter J L. Modification ofDiet in Renal Disease (MDRD) Study Group. Blood Pressure Control, Proteinuria, and the Progression ofRenal Disease. Ann Intern Med 1995; 123: 754-762
13. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J Am Soc Nephrol 2006; 17: 2974-2984 (Pubitemid 44707757)
14. Tonelli M, Klarenbach S W, Lloyd A M, James M T, Bello A K, Manns B J, Hemmelgarn B R. Higher estimated glomerular filtration rates may be associated with increased risk ofadverse outcomes, especially with concomitant proteinuria. Kidney Int 2011 [Epub ahead ofprint]; available from: http://dx.doi.org/10. 1038/ki.2011.280
15. van der Velde M, Matsushita K, Coresh J, Astor B C, Woodward M, Levey A, de Jong P, Gansevoort R T, El-Nahas M, Eckardt K-U, Kasiske B L, Ninomiya T, Chalmers J, Macmahon S, Tonelli M, Hemmelgarn B, Sacks F, Curhan G, Collins A J, Li S, Chen S-C, Hawaii Cohort K P, Lee B J, Ishani A, Neaton J, Svendsen K, Mann JfE, YusufS, Teo K K. u. a. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis ofhigh-risk population cohorts. Kidney Int 2011; 79: 1341-1352
16. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness ofaldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68 (Pubitemid 36056793)
17. Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M, Ravid M. The effect ofspironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent ofblood pressure reduction: a randomized controlled study. Diabet Med 2004; 21: 471-475 (Pubitemid 38608536)
18. Bianchi S, Bigazzi R, Campese V M. Antagonists ofaldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46: 45-51 (Pubitemid 40848432)
19. Chrysostomou A, Pedagogos E, MacGregor L, Becker G J. Double-blind, placebo-controlled study on the effect ofthe aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol 2006; 1: 256-262
20. Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T. Effect ofrenin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition ofan aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res 2008; 31: 59-67 (Pubitemid 351325616)
21. Rafiq K, Hitomi H, Nakano D, Nishiyama A. Pathophysiological Roles ofAldosterone and Mineralocorticoid Receptor in the Kidney. J Pharmacol Sci 2011; 115: 1-7
22. Epstein M, Williams G H, Weinberger M, Lewin A, Krause S, Mukherjee R, Patni R, Beckerman B. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 2006; 1: 940-951
23. Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B. Triple pharmacological blockade ofthe renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis 2008; 52: 486-493
24. Bianchi S, Bigazzi R, Campese V M. Long-term effects ofspironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int 2006; 70: 2116-2123 (Pubitemid 44871374)
25. Rossing K, Schjoedt K J, Smidt U M, Boomsma F, Parving H-H. Beneficial effects ofadding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005; 28: 2106-2112 (Pubitemid 41242452)
26. Schjoedt K J, Rossing K, Juhl T R, Boomsma F, Tarnow L, Rossing P, Parving H H. Beneficial impact ofspironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006; 70: 536-542 (Pubitemid 44141580)
27. Quinkler M, Zehnder D, Eardley K S, Lepenies J, Howie A J, Hughes S V, Cockwell P, Hewison M, Stewart P M. Increased expression ofmineralocorticoid effector mechanisms in kidney biopsies ofpatients with heavy proteinuria. Circulation 2005; 112: 1435-1443 (Pubitemid 41291769)
28. Ribstein J, Du Cailar G, Fesler P, Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol 2005; 16: 1320-1325 (Pubitemid 41716516)
29. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi L A. Relationships ofplasma renin levels with renal function in patients with primary aldosteronism. Clin J Am Soc Nephrol 2007; 2: 722-731
30. Milliez P, Girerd X, Plouin P-F, Blacher J, Safar M E, Mourad J-J. Evidence for an increased rate ofcardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248 (Pubitemid 40523144)
31. Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi L A. Long-term cardiac effects ofadrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911-918 (Pubitemid 350287534)
32. Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi L A. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80-85
33. Born-Frontsberg E, Reincke M, Rump L C, Hahner S, Diederich S, Lorenz R, Allolio B, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Endres S, Quinkler M. Cardiovascular and cerebrovascular comorbidities ofhypokalemic and normokalemic primary aldosteronism: results ofthe German Conn's Registry. J Clin Endocrinol Metab 2009; 94: 1125-1130
34. Quinkler M, Born-Frontsberg E, Fourkiotis V G. Comorbidities in primary aldosteronism. Horm Metab Res 2010; 42: 429-434
35. Reincke M, Meisinger C, Holle R, Quinkler M, Hahner S, Beuschlein F, Bidlingmaier M, Seissler J, Endres S. Is primary aldosteronism associated with diabetes mellitus? Results ofthe German Conn's Registry. Horm Metab Res 2010; 42: 435-439
36. Born-Frontsberg E, Reincke M, Beuschlein F, Quinkler M. Tumor size ofConn's adenoma and comorbidities. Horm Metab Res 2009; 41: 785-788
37. Shigematsu Y, Hamada M, Okayama H, Hara Y, Hayashi Y, Kodama K, Kohara K, Hiwada K. Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism. Hypertension 1997; 29: 723-727 (Pubitemid 27097976)
38. Nishimura M, Uzu T, Fujii T, Kuroda S, Nakamura S, Inenaga T, Kimura G. Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis 1999; 33: 261-266 (Pubitemid 29072226)
39. Rossi G P, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello M-J, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Pessina A C, Mantero F. Renal damage in primary aldosteronism: results ofthe PAPY Study. Hypertension 2006; 48: 232-238 (Pubitemid 44309817)
40. Wu V C, Yang S Y, Lin J W, Cheng B W, Kuo C C, Tsai C T, Chu T S, Huang K H, Wang S M, Lin Y H, Chiang C K, Chang H W, Lin C Y, Lin L Y, Chiu J S, Hu fC, Chueh S C, Ho Y L, Liu K L, Lin S L, Yen R F, Wu K D. Kidney impairment in primary aldosteronism. Clin Chim Acta 2011; 412: 1319 -1325
41. Reincke M, Rump L C, Quinkler M, Hahner S, Diederich S, Lorenz R, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Meisinger C, Holle R, Endres S, for the Participants ofthe German Conn's Registry. Risk Factors Associated with a Low Glomerular Filtration Rate in Primary Aldosteronism. J Clin Endocrinol Metab 2008; 94: 869-875
42. Sechi L A, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi G L, Catena C. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295: 2638
43. Dworkin L D, Feiner H D, Randazzo J. Glomerular hypertension and injury in desoxycorticosterone-salt rats on antihypertensive therapy. Kidney Int 1987; 31: 718-724 (Pubitemid 17025901)
44. Hammer F, Edwards N C, Hughes B A, Steeds R P, Ferro C J, Townend J N, Stewart P M. The effect ofspironolactone upon corticosteroid hormone metabolism in patients with early stage chronic kidney disease. Clin Endocrinol (Oxf) 2010; 73: 566-572
45. Rizzoni D, Paiardi S, Rodella L, Porteri E, De Ciuceis C, Rezzani R, Boari GE M, Zani F, Miclini M, Tiberio GA M, Giulini S M, Rosei C A, Bianchi R, Rosei E A. Changes in extracellular matrix in subcutaneous small resistance arteries ofpatients with primary aldosteronism. J Clin Endocrinol Metab 2006; 91: 2638-2642 (Pubitemid 44024630)
46. Holaj R, Zelinka T, Wichterle D, Petrák O, Štrauch B, Widimskỳ J Jr. Increased intima-media thickness ofthe common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007; 25: 1451
47. Bernini G, Galetta F, Franzoni F, Bardini M, Taurino C, Bernardini M, Ghiadoni L, Bernini M, Santoro G, Salvetti A. Arterial stiffness, intimamedia thickness and carotid artery fibrosis in patients with primary aldosteronism. J Hypertens 2008; 26: 2399
48. Min L-J, Mogi M, Li J-M, Iwanami J, Iwai M, Horiuchi M. Aldosterone and angiotensin II synergistically induce mitogenic response in vascular smooth muscle cells. Circ Res 2005; 97: 434-442 (Pubitemid 41298173)
49. Nakamura Y, Suzuki S, Suzuki T, Ono K, Miura I, Satoh F, Moriya T, Saito H, Yamada S, Ito S, Sasano H. MDM2: a novel mineralocorticoidresponsive gene involved in aldosterone-induced human vascular structural remodeling. Am J Pathol 2006; 169: 362-371 (Pubitemid 44156299)
50. Jeong Y, Chaupin D F, Matsushita K, Yamakuchi M, Cameron S J, Morrell C N, Lowenstein C J. Aldosterone activates endothelial exocytosis. Proc Natl Acad Sci USA 2009; 106: 3782-3787
51. Lemarié C A, Simeone SM C, Nikonova A, Ebrahimian T, Deschênes M-E, Coffman T M, Paradis P, Schiffrin E L. Aldosterone-induced activation ofsignaling pathways requires activity ofangiotensin type 1a receptors. Circ Res 2009; 105: 852-859
52. Novello M, Catena C, Nadalini E, Colussi G L, Baroselli S, Chiuch A, Lapenna R, Bazzocchi M, Sechi L A. Renal cysts and hypokalemia in primary aldosteronism: results oflong-term follow-up after treatment. J Hypertens 2007; 25: 1443-1450 (Pubitemid 46918832)
53. Ogasawara M, Nomura K, Toraya S, Kikuchi C, Katayama M, Ujihara M, Kono A. Clinical implications ofrenal cyst in primary aldosteronism. Endocr J 1996; 43: 261-268 (Pubitemid 126527642)
54. Sechi L A, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi G L, Catena C. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295: 2638-2645 (Pubitemid 43882339)
55. Sechi L A, Colussi GL, Di Fabio A, Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am. J. Hypertension 2010; 23: 1253-1260
56. Reams G P, Bauer J H. Effect ofenalapril in subjects with hypertension associated with moderate to severe renal dysfunction. Arch Intern Med 1986; 146: 2145-2148 (Pubitemid 17189086)
57. Freis E D. Salt, volume and the prevention ofhypertension. Circulation 1976; 53: 589-595
58. Law M R, Frost C D, Wald N J. Dietary salt and blood pressure. J Hypertens Suppl 1991; 9: S37-S41; discussion S47-S49
59. He fJ, MacGregor G A. Effect ofmodest salt reduction on blood pressure: a meta-analysis ofrandomized trials. Implications for public health. J Hum Hypertens 2002; 16: 761-770
60. Sacks fM, Svetkey L P, Vollmer W M, Appel L J, Bray G A, Harsha D, Obarzanek E, Conlin P R, Miller E R 3 rd, Simons-Morton D G, Karanja N, Lin P H. Effects on blood pressure ofreduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344: 3-10
61. Law M R, Frost C D, Wald N J. By how much does dietary salt reduction lower blood pressure? I-Analysis ofobservational data among populations. BMJ 1991; 302: 811-815
62. Frost C D, Law M R, Wald N J. By how much does dietary salt reduction lower blood pressure? II-Analysis ofobservational data within populations. BMJ 1991; 302: 815-818
63. Law M R, Frost C D, Wald N J. By how much does dietary salt reduction lower blood pressure? III-Analysis ofdata from trials ofsalt reduction. BMJ 1991; 302: 819-824
64. Pimenta E, Gaddam K K, Oparil S, Aban I, Husain S, Dell'Italia L J, Calhoun D A. Effects ofdietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54: 475-481
65. Quinkler M, Stewart P M. Hypertension and the cortisol-cortisone shuttle. J Clin Endocrinol Metab 2003; 88: 2384-2392 (Pubitemid 36724401)
66. Quinkler M, Bappal B, Draper N, Atterbury A J, Lavery G G, Walker E A, DeSilva V, Taylor N F, Hala S, Rajendra N, Stewart P M. Molecular basis for the apparent mineralocorticoid excess syndrome in the Oman population. Mol Cell Endocrinol 2004; 217: 143-149 (Pubitemid 38596639)
67. Kawai S, Ichikawa Y, Homma M. Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism ofdexamethasone in renal failure. J Clin Endocrinol Metab 1985; 60: 848-854 (Pubitemid 15085110)
68. Srivastava L S, Werk E E Jr, Thrasher K, Sholiton L J, Kozera R, Nolten W, Knowles H C Jr. Plasma cortisone concentration as measured by radioimmunoassay. J Clin Endocrinol Metab 1973; 36: 937-943
69. Whitworth J A, Stewart P M, Burt D, Atherden S M, Edwards C R. The kidney is the major site ofcortisone production in man. Clin Endocrinol (Oxf) 1989; 31: 355-361 (Pubitemid 19219243)
70. Vogt B, Frey B M, Frey fJ. 11 beta-Hydroxysteroid dehydrogenase: pathophysiology. Adv Nephrol Necker Hosp 1999; 29: 127-148
71. Riddle M C, McDaniel P A. Renal 11 beta-hydroxysteroid dehydrogenase activity is enhanced by ramipril and captopril. J Clin Endocrinol Metab 1994; 78: 830-834 (Pubitemid 24118073)
72. Quinkler M, Zehnder D, Lepenies J, Petrelli M D, Moore J S, Hughes S V, Cockwell P, Hewison M, Stewart P M. Expression ofrenal 11betahydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function. Eur J Endocrinol 2005; 153: 291
73. Liu Y J, Nakagawa Y, Toya K, Wang Y, Saegusa H, Nakanishi T, Ohzeki T. Effects ofspironolactone on systolic blood pressure in experimental diabetic rats. Kidney Int 2000; 57: 2064-2071 (Pubitemid 30252298)
74. Greene E L, Kren S, Hostetter T H. Role ofaldosterone in the remnant kidney model in the rat. J Clin Invest 1996; 98: 1063
75. Blasi E R, Rocha R, Rudolph A E, Blomme EA G, Polly M L, McMahon E G. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 2003; 63: 1791-1800 (Pubitemid 36513325)
76. Amar L, Azizi M, Menard J, Peyrard S, Watson C, Plouin P-F. Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism. Hypertension 2010; 56: 831-838
77. Lea W B, Kwak E S, Luther J M, Fowler S M, Wang Z, Ma J, Fogo A B, Brown N J. Aldosterone antagonism or synthase inhibition reduces endorgan damage induced by treatment with angiotensin and high salt. Kidney Int 2009; 75: 936-944
78. Rigel D F, Fu F, Beil M, Hu C-W, Liang G, Jeng A Y. Pharmacodynamic and pharmacokinetic characterization ofthe aldosterone synthase inhibitor FAD286 in two rodent models ofhyperaldosteronism: comparison with the 11beta-hydroxylase inhibitor metyrapone. J Pharmacol Exp Ther 2010; 334: 232-243
79. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, Dechend R, Wellner M, Meiners S, Maser-Gluth C, Jeng A Y, Webb R L, Luft fC, Muller D N. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005; 111: 3087-3094 (Pubitemid 40847786)
80. Fujisawa G, Okada K, Muto S, Fujita N, Itabashi N, Kusano E, Ishibashi S. Spironolactone prevents early renal injury in streptozotocininduced diabetic rats. Kidney Int 2004; 66: 1493-1502 (Pubitemid 39298382)
81. Sun G-P, Kohno M, Guo P, Nagai Y, Miyata K, Fan Y-Y, Kimura S, Kiyomoto H, Ohmori K, Li D-T, Abe Y, Nishiyama A. Involvements ofRhokinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 2006; 17: 2193-2201 (Pubitemid 44141909)
82. Pérez-Rojas J, Blanco J A, Cruz C, Trujillo J, Vaidya V S, Uribe N, Bonventre J V, Gamba G, Bobadilla N A. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2007; 292: F131-F139 (Pubitemid 46105252)
83. Nagase M. Activation ofthe aldosterone/mineralocorticoid receptor system in chronic kidney disease and metabolic syndrome. Clin Exp Nephrol 2010; 14: 303-314
84. Toyonaga J, Tsuruya K, Ikeda H, Noguchi H, Yotsueda H, Fujisaki K, Hirakawa M, Taniguchi M, Masutani K, Iida M. Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol Dial Transplant 2011; 26: 2475-2484
85. Chen C, Liang W, Jia J, van Goor H, Singhal P C, Ding G. Aldosterone Induces Apoptosis in Rat Podocytes: Role ofPI3-K/Akt and p38MAPK Signaling Pathways. Nephron Exp Nephrol 2009; 113: e26-e34
86. Friis S, Sørensen H T, Mellemkjaer L, McLaughlin J K, Nielsen G L, Blot W J, Olsen J H. Angiotensin-converting enzyme inhibitors and the risk ofcancer: a population-based cohort study in Denmark. Cancer 2001; 92: 2462-2470 (Pubitemid 33029093)
87. Moore L E, Wilson R T, Campleman S L. Lifestyle factors, exposures, genetic susceptibility, and renal cell cancer risk: a review. Cancer Invest 2005; 23: 240-255 (Pubitemid 40770742)
88. Schupp N, KolkhofP, Queisser N, Gärtner S, Schmid U, Kretschmer A, Hartmann E, Oli R G, Schäfer S, Stopper H. Mineralocorticoid receptormediated DNA damage in kidneys ofDOCA-salt hypertensive rats. FASEB J 2011; 25: 968
89. Grossman E, Messerli fH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med 2002; 112: 479-486 (Pubitemid 34450709)
90. Fan Y-Y, Kohno M, Hitomi H, Kitada K, Fujisawa Y, Yatabe J, Yatabe M, Felder R A, Ohsaki H, Rafiq K, Sherajee S J, Noma T, Nishiyama A, Nakano D. Aldosterone/Mineralocorticoid Receptor Stimulation Induces Cellular Senescence in the Kidney. Endocrinology 2010; 152: 680-688
91. Schmidt B M. Rapid non-genomic effects ofaldosterone on the renal vasculature. Steroids 2008; 73: 961-965
92. Wehling M. Specific, nongenomic actions ofsteroid hormones. Annu Rev Physiol 1997; 59: 365-393 (Pubitemid 27142447)
93. Vinson G P, Coghlan J P. Expanding view ofaldosterone action, with an emphasis on rapid action. Clin Exp Pharmacol Physiol 2010; 37: 410-416
94. Griol-Charhbili V, Fassot C, Messaoudi S, Perret C, Agrapart V, Jaisser F. Epidermal growth factor receptor mediates the vascular dysfunction but not the remodeling induced by aldosterone/salt. Hypertension 2011; 57: 238-244
95. Huang S, Zhang A, Ding G, Chen R. Aldosterone-induced mesangial cell proliferation is mediated by EGfreceptor transactivation. Am J Physiol-Renal Physiol 2009; 296: F1323
96. Sinphitukkul K, Eiam-Ong S, Manotham K, Eiam-Ong S. Nongenomic effects ofaldosterone on renal protein expressions ofpEGFR and pERK1/2 in rat kidney. Am J Nephrol 2011; 33: 111-120
97. Molnar G A, Lindschau C, Dubrovska G, Mertens P R, Kirsch T, Quinkler M, Gollasch M, Wresche S, Luft fC, Muller D N, Fiebeler A. Glucocorticoid- Related Signaling Effects in Vascular Smooth Muscle Cells. Hypertension 2008; 51: 1372-1378 (Pubitemid 351555952)
98. Young M J, Morgan J, Brolin K, Fuller P J, Funder J W. Activation ofMineralocorticoid Receptors by Exogenous Glucocorticoids and the Development ofCardiovascular Inflammatory Responses in Adrenalectomized Rats. Endocrinology 2010; 151: 2622-2628
99. Lam EY M, Funder J, Nikolic-Paterson D, Fuller P J, Young M J. Mineralocorticoid Receptor Blockade But Not Steroid Withdrawal Reverses Renal Fibrosis in Deoxycorticosterone/Salt Rats. Endocrinology 2006; 147: 3623-3629 (Pubitemid 43901155)
100. Ou X M, Storring J M, Kushwaha N, Albert P R. Heterodimerization ofmineralocorticoid and glucocorticoid receptors at a novel negative response element ofthe 5-HT1A receptor gene. J Biol Chem 2001; 276: 14299-14307
101. Tsugita M, Iwasaki Y, Nishiyama M, Taguchi T, Shinahara M, Taniguchi Y, Kambayashi M, Nishiyama A, Gomez-Sanchez C E, Terada Y, Hashimoto K. Glucocorticoid receptor plays an indispensable role in mineralocorticoid receptor-dependent transcription in GR-deficient BE(2)C and T84 cells in vitro. Mol Cell Endocrinol 2009; 302: 18-25
102. Nishi M, Kawata M. Dynamics ofglucocorticoid receptor and mineralocorticoid receptor: implications from live cell imaging studies. Neuroendocrinology 2007; 85: 186-192 (Pubitemid 46878908)
103. Nishi M, Tanaka M, Matsuda K, Sunaguchi M, Kawata M. Visualization ofglucocorticoid receptor and mineralocorticoid receptor interactions in living cells with GFP-based fluorescence resonance energy transfer. J Neurosci 2004; 24: 4918-4927 (Pubitemid 38697824)
104. Magariños A M, McEwen B S, Flügge G, Fuchs E. Chronic psychosocial stress causes apical dendritic atrophy ofhippocampal CA3 pyramidal neurons in subordinate tree shrews. J Neurosci 1996; 16: 3534-3540 (Pubitemid 26142382)
105. De Kloet E R, Vreugdenhil E, Oitzl M S, Joëls M. Brain corticosteroid receptor balance in health and disease. Endocr Rev 1998; 19: 269-301 (Pubitemid 29117816)